New hope for tough lymphoma: experimental drug IMV101 enters human testing

NCT ID NCT07376642

First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 12 times

Summary

This study tests a new drug, IMV101, in 30 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer. The main goals are to check the drug's safety and find the best dose. Researchers will also see if the drug can shrink tumors or slow the cancer's growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Boren Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100070, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cancer Hospital Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhengzhou Yihe Hospital

    RECRUITING

    Zhengzhou, Henan, 450047, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.